Nisa Investment Advisors LLC purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the third quarter, Holdings Channel.com reports. The institutional investor purchased 7,700 shares of the company’s stock, valued at approximately $621,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Renaissance Capital LLC increased its holdings in Tempus AI by 26.9% in the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after buying an additional 17,866 shares in the last quarter. Pier 88 Investment Partners LLC acquired a new position in Tempus AI in the 2nd quarter worth about $286,000. Blair William & Co. IL boosted its position in Tempus AI by 109.2% during the second quarter. Blair William & Co. IL now owns 67,637 shares of the company’s stock worth $4,298,000 after purchasing an additional 35,303 shares in the last quarter. Trivium Point Advisory LLC grew its holdings in Tempus AI by 670.7% in the second quarter. Trivium Point Advisory LLC now owns 38,627 shares of the company’s stock valued at $2,454,000 after purchasing an additional 33,615 shares during the period. Finally, EFG Asset Management North America Corp. acquired a new position in shares of Tempus AI during the 2nd quarter worth approximately $2,233,000. Institutional investors and hedge funds own 24.22% of the company’s stock.
Tempus AI Price Performance
Tempus AI stock opened at $68.92 on Friday. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The company has a 50-day moving average price of $69.19 and a 200 day moving average price of $73.36. Tempus AI, Inc. has a 12-month low of $32.90 and a 12-month high of $104.32. The stock has a market cap of $12.26 billion, a P/E ratio of -57.92 and a beta of 5.22.
Wall Street Analysts Forecast Growth
TEM has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. TD Cowen cut Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price target for the company. in a research report on Tuesday, October 21st. Guggenheim upped their target price on shares of Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, September 26th. Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Finally, BTIG Research increased their price target on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $87.20.
View Our Latest Research Report on Tempus AI
Insiders Place Their Bets
In other news, CFO James William Rogers sold 19,966 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the completion of the transaction, the chief financial officer directly owned 111,250 shares in the company, valued at approximately $8,143,500. This represents a 15.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Eric P. Lefkofsky sold 332,500 shares of the firm’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $89.11, for a total value of $29,629,075.00. Following the sale, the chief executive officer directly owned 9,074,532 shares of the company’s stock, valued at $808,631,546.52. The trade was a 3.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 932,832 shares of company stock valued at $71,184,024. 26.27% of the stock is currently owned by insiders.
About Tempus AI
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Stories
- Five stocks we like better than Tempus AI
- Buy Alert: $8 AI Stock
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Trump just signed it
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Virtually Unknown AI Company Solving Trillion-Dollar Problem
Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
